Home › Breast Cancer
Breast Cancer clinical trials recruiting in the U.S.
670 studies for Breast Cancer are recruiting participants at sites across the United States.
Breast cancer is a cancer that starts in the breast tissue, when cells change and grow out of control. Learn about the types, diagnosis, and treatments.
Cities with the most studies
- New York City, NY144 studies
- Houston, TX126 studies
- Boston, MA110 studies
- Nashville, TN78 studies
- Los Angeles, CA73 studies
- Edison, NJ70 studies
- Queens, NY67 studies
- Durham, NC63 studies
- St. Louis, MO63 studies
- Chicago, IL59 studies
- Dallas, TX54 studies
- Philadelphia, PA51 studies
- Arlington, VA50 studies
- Greenburgh, NY45 studies
- San Antonio, TX45 studies
- Washington, DC44 studies
- Baltimore, MD44 studies
- Staten Island, NY43 studies
- Baldwin Park, CA43 studies
- Miami, FL42 studies
- Pittsburgh, PA42 studies
- Atlanta, GA42 studies
- New Rochelle, NY41 studies
- San Diego, CA41 studies
- San Francisco, CA40 studies
- Tampa, FL40 studies
- Columbus, OH39 studies
- Rochester, MN39 studies
- East Norwalk, CT38 studies
- Jacksonville, FL38 studies
- New Haven, CT38 studies
- Seattle, WA37 studies
- Kansas City, MO34 studies
- Detroit, MI34 studies
- Portland, OR33 studies
- Cleveland, OH33 studies
- Aurora, CO30 studies
- Santa Monica, CA29 studies
- Mountain View, CA27 studies
- Salt Lake City, UT27 studies
By state
- Alabama32 studies
- Alaska8 studies
- Arizona55 studies
- Arkansas17 studies
- California180 studies
- Colorado56 studies
- Connecticut50 studies
- Delaware9 studies
- District of Columbia27 studies
- Florida144 studies
- Georgia52 studies
- Hawaii11 studies
- Idaho7 studies
- Illinois81 studies
- Indiana31 studies
- Iowa23 studies
- Kansas26 studies
- Kentucky23 studies
- Louisiana21 studies
- Maine16 studies
- Maryland65 studies
- Massachusetts116 studies
- Michigan72 studies
- Minnesota64 studies
- Mississippi9 studies
- Missouri73 studies
- Montana13 studies
- Nebraska26 studies
- Nevada22 studies
- New Hampshire18 studies
- New Jersey94 studies
- New Mexico20 studies
- New York184 studies
- North Carolina91 studies
- North Dakota9 studies
- Ohio77 studies
- Oklahoma20 studies
- Oregon41 studies
- Pennsylvania91 studies
- Rhode Island12 studies
- South Carolina22 studies
- South Dakota17 studies
- Tennessee90 studies
- Texas176 studies
- Utah42 studies
- Vermont5 studies
- Virginia84 studies
- Washington50 studies
- West Virginia14 studies
- Wisconsin44 studies
- Wyoming3 studies
Recently updated studies
WashU DIEP Flap Video and Patient Understanding Improvement
Recruiting
Ages 18 and older · Women · Updated Nov 13, 2026 · NCT06864754Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Nov 13, 2026 · NCT07619534Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07360314A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07748208Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT05696626PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07069595A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT05894239A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
RecruitingPhase 1
Ages 18 to 55 · Women · Updated Nov 12, 2026 · NCT07310420Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
Recruiting
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT05649072Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06797635Multi-center MRD Registry for Inflammatory Breast Cancer
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06966050A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07827573Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)
Recruiting
Ages 70 and older · All sexes · Updated Nov 12, 2026 · NCT07629206An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07222267A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT07541079BostonGene and Exigent Genomic INsight Study
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06272864Genomic Services Research Program
RecruitingObservational study
1 Month – 105 Years · All sexes · Updated Nov 12, 2026 · NCT02595957Utility of a Mobile Application for Young Women With Breast Cancer
Recruiting
Ages 18 to 45 · Women · Updated Nov 12, 2026 · NCT07009093S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03418961Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Nov 12, 2026 · NCT05372640Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RecruitingPhase 2
Ages 18 to 72 · All sexes · Updated Nov 12, 2026 · NCT01174121Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
RecruitingPhase 1/2
All ages · All sexes · Updated Nov 12, 2026 · NCT06590857Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy
Recruiting
Ages 18 to 80 · Women · Updated Nov 12, 2026 · NCT05245812A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07905001Pilot Study of Hydroxychloroquine for the Treatment of AIMSS
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07825454From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.